ClinicalTrials.gg
Not yet recruitingNCT07632599Updated Jun 8, 2026

Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis

A Phase 1 interventional study of IV administration of CG-BM1 and Placebo in Ankylosing Spondylitis, sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
54th of 62
40 · median 150
Started
2026
with 7 others
Phase 1
4 of 77
3 open now
Primary completion
2027-06
later than 12 of 22 live
Registered
73rd of 77
by date

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 54th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 12 of the 22 other live ones, and was the 73rd registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if allogeneic human bone marrow-derived mesenchymal stem cells (CG-BM1) are safe and show preliminary efficacy in treating patients with ankylosing spondylitis (AS). It will also explore the appropriate dose of CG-BM1.

The main questions it aims to answer are:

What medical problems (adverse events) do participants have when taking CG-BM1? (Safety and tolerability)

Does CG-BM1 improve disease activity, pain, and function in patients with AS? (Preliminary efficacy)

Researchers will compare CG-BM1 to a placebo (an inactive substance that looks like CG-BM1) in the second phase of the study to see if CG-BM1 works for AS.

This study has two phases:

Phase 1 (dose-escalation): Open-label, single-arm. Participants will receive one of three escalating doses of CG-BM1 weekly for 4 weeks.

Phase 2 (dose-expansion): Randomized, double-blind, placebo-controlled. Participants will receive either the recommended dose of CG-BM1 or a placebo weekly for 4 weeks, in addition to standard background therapy (celecoxib).

Participants will:

Receive CG-BM1 or placebo via intravenous infusion once a week for 4 weeks

Visit the clinic for follow-up assessments at Week 1, 4, 8, 12, and 24 after the first infusion

Undergo physical exams, laboratory tests (blood and urine), and complete questionnaires about disease activity, pain, and function (e.g., BASDAI, VAS, ASAS response criteria)

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for ankylosing spondylitis (AS)
  • Age 18 to 40 years
  • Must be able to understand and communicate with the investigator, comply with study requirements, and provide signed and dated before any study assessments are performed
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) total score ≥ 4 (0-10 scale), and total back pain measured by VAS ≥ 40 mm (0-100 mm)
  • CRP or ESR elevated ≥ 1.5 times the
  • Patients taking methotrexate (≤ 25 mg/week) or sulfasalazine (≤ 3 g/day) are permitted to continue these medications, provided they have been used for at least 3 months and maintained at a stable dose for at least 4 weeks prior to randomization. Patients taking methotrexate must maintain stable folic acid supplementation prior to randomization
  • Patients taking DMARDs other than methotrexate and sulfasalazine must discontinue them at least 4 weeks prior to randomization
  • No prior use of any form of biologics within 6 months
  • Spinal X-ray must rule out complete rigid ankylosis

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any component of the study drug (primarily bone marrow mesenchymal stem cells; include dimethyl sulfoxide, human albumin, etc.)
  • Current evidence of infection or as shown by chest X-ray or MRI within 3 months prior to screening
  • Currently using potent opioid analgesics
  • Received any intra-articular injection therapy (e.g., ) within 4 weeks prior to randomization
  • Received any intramuscular corticosteroid injection within 2 weeks prior to randomization
  • Received traditional Chinese medicine treatment for AS within 4 weeks prior to randomization
  • Pregnant or breastfeeding women
  • Presence of underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal disease that, in the investigator's opinion, would place the patient at unacceptable risk if treated with immunomodulatory agents
  • Significant health problem or disease including (but not limited to): uncontrolled hypertension (≥ 160/95 mmHg), congestive heart failure, uncontrolled diabetes, or extremely poor functional status rendering the patient unable to care for themselves
  • History of renal impairment, glomerulonephritis, or a single kidney, or serum creatinine level > 1.5 mg/dL
  • Active systemic infection within 2 weeks prior to randomization (common cold excluded)
  • Current infection or history of chronic, recurrent infectious disease, or clinical test suggesting tuberculosis (including latent tuberculosis)
  • Known infection, , or at screening or randomization
  • History or evidence of alcohol or drug abuse within 6 months prior to randomization
  • History of lymphoproliferative disease or known malignancy of any organ system within the past 5 years
  • Pulmonary arterial hypertension class III or IV (WHO functional classification) at screening
  • History of deep vein thrombosis at screening, or history of pulmonary embolism within 3 months prior to screening
  • Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study (e.g., lack of compliance, difficulty in long-term follow-up)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    phase 1:CG-BM1 Dose Escalation Cohorts

    Participants will be sequentially assigned to one of three dose cohorts using a "3+3" design: low-dose (1\*10\^6 cells/kg), medium-dose (2.0\*10\^6 cells/kg), or high-dose 4.0\*10\^6 cells/kg). In each cohort, CG-BM1 will be administered via intravenous infusion once weekly for a total of 4 doses on Days 0, 7, 14, and 21. All participants across all cohorts will concurrently receive standard background therapy consisting of celecoxib 0.2g orally once daily.

    Biological: IV administration of CG-BM1

  • Placebo comparator
    phase 2 :placebo Cohorts

    Participants will be randomized to receive the placebo (Compound Electrolyte Injection) via intravenous (IV) infusion once weekly for a total of 4 doses, mimicking the regimen of the experimental group. All participants will simultaneously receive a background therapy of celecoxib 0.2g orally once daily.

    Biological: Placebo

  • Experimental
    phase 2 :CG-BM1 Cohorts

    Participants will be randomized to receive CG-BM1 at the clinically recommended dose (determined by the Safety Review Committee based on Phase 1 results) via intravenous (IV) infusion once weekly for a total of 4 doses. All participants will simultaneously receive a background therapy of celecoxib 0.2g orally once daily.

    Biological: CG-BM1

Interventions

  • BiologicalIV administration of CG-BM1

    Dose level 1: CG-BM1 1.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily Dose level 2: CG-BM1 2.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily Dose level 3: CG-BM1 4.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily

  • BiologicalPlacebo

    Sodium Chloride Solution, 5 ml, IV, weekly × 4+ celecoxib, 0.2g, p.o. daily

  • BiologicalCG-BM1

    CG-BM1 \[recommended dose\], IV, weekly × 4 + celecoxib, 0.2g, p.o. daily

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 24 weeks

  2. Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of Participants Achieving ASAS20 Response

    ASAS20 response is defined as an improvement of \> 20% and an absolute improvement of \> 1 unit (on a 0-10 scale) or \> 10 mm (on a 0-100 mm scale) in at least 3 of the following 4 domains: Patient Global Assessment, Physical Function (BASFI), Total Spinal Pain, and Inflammation (Morning Stiffness). Additionally, there must be no worsening in the remaining domain.

    Time frame: Weeks 1, 4, 8, 12, and 24

  2. Global Assessment of Disease Activity

    Evaluated using a 0-10 Visual Analog Scale (VAS), where 0 indicates "not active" and 10 indicates "very active". Higher scores represent greater disease activity. The outcome will report the change from baseline values at each subsequent visit timepoint.

    Time frame: Weeks 1, 4, 8, 12, and 24

  3. Total Spinal Pain Intensity Score

    Measured by a Visual Analog Scale (VAS) ranging from 0 mm (no pain) to 100 mm (severe pain), calculating the average score of overall spinal pain and nocturnal spinal pain over the past week. Higher scores represent worse pain intensity.

    Time frame: Weeks 1, 4, 8, 12, and 24

  4. Bath Ankylosing Spondylitis Functional Index (BASFI)

    BASFI consists of 10 items assessing the patient's ability to perform specific activities of daily living. Each item is scored on a 0-10 scale (0 = easy, 10 = impossible). The total score is calculated as the mean of the 10 scores, where a higher score indicates more severe functional impairment.

    Time frame: Weeks 1, 4, 8, 12, and 24

  5. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI evaluates 6 items: fatigue, spine pain, peripheral joint pain, localized tenderness, morning stiffness severity, and morning stiffness duration over the past week, each on a 0-10 scale. The final score is calculated as the average of the first 4 items plus the average of the two morning stiffness items, with a total range of 0 to 10. Higher scores indicate more severe disease activity.

    Time frame: Weeks 1, 4, 8, 12, and 24

  6. Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI evaluates spinal mobility based on 5 clinical measurements: cervical rotation, tragus-to-wall distance, lumbar flexion (modified Schober's test), lumbar side flexion, and intermalleolar distance. Each component is scored linearly from 0 to 2, with a total composite score ranging from 0 to 10. Higher scores indicate more severe impairment of spinal mobility.

    Time frame: Weeks 1, 4, 8, 12, and 24

  7. Swollen Joint Count(SJC) and Tender Joint Count(TJC) Based on 44-Joint Assessment

    Peripheral arthritis progression will be evaluated via the standard 44-joint count assessment. Scores range from 0 to 44 joints, where a reduction in count indicates therapeutic improvement.

    Time frame: Weeks 1, 4, 8, 12, and 24

  8. Serum C-reactive Protein (CRP) Concentration (mg/L)

    Evaluated via peripheral blood samples to explore the systemic anti-inflammatory effect of CG-BM1.

    Time frame: Weeks 1, 4, 8, 12, and 24

  9. Erythrocyte Sedimentation Rate (ESR) (mm/h)

    Evaluated via peripheral blood samples to explore the systemic anti-inflammatory effect of CG-BM1.

    Time frame: Weeks 1, 4, 8, 12, and 24

  10. Serum Concentrations of Cytokines (TNF-α and BMP2) (pg/mL)

    Measured via enzyme-linked immunosorbent assay (ELISA) from collected serum samples to investigate the mechanistic pathways of bone remodeling and immune regulation.

    Time frame: Weeks 1, 4, 8, 12, and 24

  11. Peripheral Blood Immune Cell Subset Percentages

    Evaluated via multicolour flow cytometry to quantify the percentages of CD4+ T cells, CD8+ T cells, Treg cells, Th17 cells, NK cells, MAIT cells, monocytes, neutrophils, and B cells relative to total lymphocytes or leukocytes, in order to track immune homeostasis reconstruction.

    Time frame: Weeks 1, 4, 8, 12, and 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 8, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632599
Lead sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Collaborators
Guangzhou Cellgenes Biotechnology Co.,Ltd
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Prof.Wang
Contact
wangp57@mail.sysu.edu.cn
86+138 2602 4785

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion